Differential behavioral outcomes of 3,4-methylenedioxymethamphetamine (MDMA-ecstasy) in anxiety-like responses in mice

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 5, 2011, Pages 428-437

  Ferraz de Paula, V ^a   Stankevicius, D ^a   Ribeiro, A ^a   Pinheiro, M L ^a   Rodrigues Costa, E C ^a   Florio, J C ^a   Lapachinske, S F ^a   Moreau, R L M ^a   Palermo Neto, J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Corticosterone; Ecstasy; Hole board; Open field; Plus maze; Predator odor test

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CORTICOSTERONE; DOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; MALE; MOUSE; NONHUMAN;

MUS; RODENTIA;

EID: 79958070726     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500046     Document Type: Article

References (40)

1. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001; 16: 589-598.
2. De La Torre R, Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004; 25: 505-508.
3. de Paula V, Ribeiro A, Pinheiro ML, Sakai M, Lacava MC, Lapachinske SF, et al. Methylenedioxymethamphetamine (Ecstasy) decreases neutrophil activity and alters leukocyte distribution in bone marrow, spleen and blood. Neuroimmunomodulation 2009; 16: 191-200.
4. Connor TJ. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 2004; 111: 357-367.
5. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, et al. Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans. Life Sci 2001; 69: 2931-2941.
6. Boyle NT, Connor TJ. MDMA ("Ecstasy") suppresses the innate IFN-gamma response in vivo: a critical role for the anti-inflammatory cytokine IL-10. Eur J Pharmacol 2007; 572: 228-238.
7. Palenicek T, Votava M, Bubenikova V, Horacek J. Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 2005; 86: 546-553.
8. Morley KC, McGregor IS. (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. Eur J Pharmacol 2000; 408: 41-49.
9. Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 2002; 159: 167-175.
10. Navarro JF, Maldonado E. Behavioral profile of 3,4-methylenedioxymethamphetamine (MDMA) in agonistic encounters between male mice. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 327-334.
11. Maldonado E, Navarro JF. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 463-472.
12. Lin HQ, Burden PM, Christie MJ, Johnston GA. The anxiogenic- like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 1999; 62: 403-408.
13. Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Palermo-Neto J. Dose-response effects of systemic anandamide administration in mice sequentially submitted to the open field and elevated plus-maze tests. Braz J Med Biol Res 2009; 42: 556-560.
14. Palermo-Neto J, de Oliveira MC, Robespierre de Souza W. Effects of physical and psychological stressors on behavior, macrophage activity, and Ehrlich tumor growth. Brain Behav Immun 2003; 17: 43-54.
15. Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 1998; 350: 21-29.
16. Lacava M, Ferraz-de-Paula V, Lapachinske SF, Palermo-Neto J, Moreau RLM. Simultaneous determination of methylenodioxymethamphetamine (MDMA) and methylenodioxyamphetamine (MDA) in plasma by gas chromatography with nitrogen-phosphorus detection (GC-NPD) and in vitro effects on the neutrophil activity of mice. III Encuentro Regional de Toxicologia Forense. Bogotá: TIAFT; 2007. p 97-104.
17. File SE, Wardill AG. Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacologia 1975; 44: 53-59.
18. Yang M, Augustsson H, Markham CM, Hubbard DT, Webster D, Wall PM, et al. The rat exposure test: a model of mouse defensive behaviors. Physiol Behav 2004; 81: 465-473.
19. Felicio LF, Florio JC, Sider LH, Cruz-Casallas PE, Bridges RS. Reproductive experience increases striatal and hypothalamic dopamine levels in pregnant rats. Brain Res Bull 1996; 40: 253-256.
20. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167.
21. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185.
22. Fraser LM, Brown RE, Hussin A, Fontana M, Whittaker A, O'Leary TP, et al. Measuring anxiety- and locomotionrelated behaviours in mice: a new way of using old tests. Psychopharmacology 2010; 211: 99-112.
23. Clement Y, Le Guisquet AM, Venault P, Chapouthier G, Belzung C. Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation. PLoS One 2009; 4: e7745.
24. Treit D, Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988; 31: 959-962.
25. Bubar MJ, Pack KM, Frankel PS, Cunningham KA. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 2004; 173: 326-336.
26. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 1995; 118: 316-323.
27. Fletcher PJ, Korth KM, Robinson SR, Baker GB. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology 2002; 162: 282-291.
28. Blanchard DC, Griebel G, Blanchard RJ. Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1177-1185.
29. Blanchard R, Blanchard DC. Ethological models of fear and angry aggression. Clin Neuropharmacol 1986; 9 (Suppl 4): 383-385.
30. Blanchard DC, Griebel G, Blanchard RJ. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 2003; 463: 97-116.
31. Maldonado E, Navarro JF. MDMA ("ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res 2001; 44: 27-31.
32. Tanaka M, Kohno Y, Nakagawa R, Ida Y, Takeda S, Nagasaki N. Time-related differences in noradrenaline turnover in rat brain regions by stress. Pharmacol Biochem Behav 1982; 16: 315-319.
33. Iimori K, Tanaka M, Kohno Y, Ida Y, Nakagawa R, Hoaki Y, et al. Psychological stress enhances noradrenaline turnover in specific brain regions in rats. Pharmacol Biochem Behav 1982; 16: 637-640.
34. Onur OA, Walter H, Schlaepfer TE, Rehme AK, Schmidt C, Keysers C, et al. Noradrenergic enhancement of amygdale responses to fear. Soc Cogn Affect Neurosci 2009; 4: 119-126.
35. de la Mora MP, Gallegos-Cari A, Arizmendi-Garcia Y, Marcellino D, Fuxe K. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. Prog Neurobiol 2010; 90: 198-216.
36. Graham DR, Sidhu A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 2010; 88: 1777-1783.
37. Pena-Oliver Y, Buchman VL, Stephens DN. Lack of involvement of alpha-synuclein in unconditioned anxiety in mice. Behav Brain Res 2010; 209: 234-240.
38. de Kloet ER, Rosenfeld P, Van Eekelen JA, Sutanto W, Levine S. Stress, glucocorticoids and development. Prog Brain Res 1988; 73: 101-120.
39. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, et al. Immunomodulating activity of MDMA. Ann N Y Acad Sci 2000; 914: 215-224.
40. Blanchard DC, Blanchard RJ. What can animal aggression research tell us about human aggression? Horm Behav 2003; 44: 171-177.